Researchers discovered that SQ109, an antimycobacterial drug, can effectively kill Cryptococcus fungi that cause serious brain infections in people with weakened immune systems. Unlike current treatments, cryptococcal cells don’t easily develop resistance to SQ109, and it works even better when combined with fluconazole. In mouse studies, SQ109 successfully treated cryptococcal infections, suggesting it could be a valuable new treatment option for patients worldwide, especially in resource-limited regions.